Humira Biosimilar Market, By Product Type, By Indication, By Distribution Channel, By Patient Age, By Geography
상품코드:1741193
리서치사:Coherent Market Insights
발행일:2025년 03월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 휴미라 바이오시밀러 시장은 2025년 15억 4,050만 달러로 추정되고, 2032년까지 77억 2,400만 달러에 이를 것으로 예측되묘, 2025년부터 2032년까지 CAGR 25.9%로 추이할 것으로 예측되고 있습니다.
보고 범위
보고서 세부정보
기준연도
2024년
2025년 시장 규모
15억 4,050만 달러
실적 데이터
2020-2024년
예측 기간
2025-2032년
예측 기간: 2025-2032년 CAGR
25.90%
2032년 금액 예측
77억 2,400만 달러
휴미라는 건선과 류마티스 관절염과 같은 자가면역 질환을 치료하는 데 사용되는 생물학적 제제이며, 세계에서 가장 인기 있는 생물학적 제제입니다. 바이오시밀러 의약품은 보다 경제적인 치료 옵션을 제공함으로써 비용을 낮추고 필수적인 의약품에 대한 환자의 접근을 개선하는 데 도움이 됩니다. 경쟁은 가격을 낮추고 환자의 접근성을 향상시키고 궁극적으로 건강 관리 결과를 향상시킵니다.
시장 역학
특허 부족, 비용 절감, 자가면역 질환의 유병률 증가, 양호한 규제 환경은 예측 기간 동안 세계 휴미라 바이오시밀러 시장의 성장을 가속할 것으로 예상되는 주요 요인입니다.
예를 들어, 북미에서는 복수의 휴미라 바이오시밀러가 승인 및 도입되고 있어 바이오시밀러의 채용 시장을 리드하고 있습니다.
그러나 복잡한 규제 과정, 지적 재산 및 특허에 관한 소송, 의사와 환자의 의식 등이 예측 기간 동안 세계 뇌 혈관 촬영 시장의 성장을 방해할 것으로 예측됩니다.
본 조사의 주요 특징
본 보고서에서는 세계의 휴미라 바이오시밀러 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모와 CAGR을 제공합니다.
또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
또 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역에 의한 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
본 보고서에서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 파라미터를 바탕으로 세계의 휴미라 바이오시밀러 시장의 주요 기업 프로파일을 제공합니다.
본 보고서로부터 통찰에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 출시, 유형, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
휴미라 바이오시밀러 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 산업의 다양한 이해 관계자에 대응하고 있습니다.
이해관계자는 세계의 휴미라 바이오시밀러 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적과 전제조건
조사 목적
전제조건
약어
제2장 시장 전망
보고서 설명
시장 정의와 범위
주요 요약
Coherent Opportunity Map (COM)
제3장 시장 역학, 규제, 동향 분석
시장 역학
특허 유효기간
비용 절감
자가면역질환의 유병률 증가
바람직한 규제 환경
시장 성장 억제요인
시장 기회
규제 시나리오
제품 출시/승인
PEST 분석
Porter's Five Forces 분석
합병, 인수, 콜라보레이션
제4장 세계의 휴미라 바이오시밀러 시장 - 코로나 바이러스(COVID-19) 팬데믹의 영향
COVID-19 역학
공급측과 수요측의 분석
경제에 미치는 영향
제5장 세계의 휴미라 바이오시밀러 시장 : 제품 유형별, 2020-2032년
소개
바이오시밀러 휴미라(아달리무맙)
호환성 바이오시밀러 휴미라
제6장 세계의 휴미라 바이오시밀러 시장 : 적응증별, 2020-2032년
소개
류마티스 관절
건선
크론병
궤양성 대장염
강직성 척추염
청소년 특발성 관절염
기타 자가면역질환
제7장 세계의 휴미라 바이오시밀러 시장 : 환자 연령별, 2020-2032년
소개
성인 환자
소아 환자
노인 환자
제8장 세계의 휴미라 바이오시밀러 시장 : 유통 채널별, 2020-2032년
소개
병원 약국
소매 약국
온라인 약국
제9장 세계의 휴미라 바이오시밀러 시장 : 지역별, 2020-2032년
소개
북미
미국
캐나다
유럽
영국
독일
이탈리아
프랑스
스페인
러시아
기타 유럽
아시아태평양
중국
인도
일본
ASEAN 국가
호주
한국
기타 아시아태평양
라틴아메리카
브라질
멕시코
아르헨티나
기타 라틴아메리카
중동
GCC 국가
이스라엘
기타 중동
아프리카
북아프리카
중앙 아프리카
남아프리카
제10장 경쟁 구도
기업 프로파일
Amgen Inc.
Samsung Bioepis Co.
Sandoz International GmbH(Novartis AG)
Mylan NV
Boehringer Ingelheim International GmbH
Pfizer Inc.
Fresenius Kabi AG
Coherus BioSciences
Biogen Inc
AbbVie Inc
Celltrion Inc.
Rani Therapeutics Holdings, Inc.
Teva Pharmaceutical Industries Ltd
Merck & Co
Viatris Inc.
Alvotech
Analysts'Views
제11장 섹션
참고문헌
조사 방법
출판사에 대해
JHS
영문 목차
영문목차
Humira Biosimilar Market is estimated to be valued at USD 1,540.5 Mn in 2025 and is expected to reach USD 7,724.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 25.9% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 1,540.5 Mn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
25.90%
2032 Value Projection:
USD 7,724.0 Mn
Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.
Market Dynamics
Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.
For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.
However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.
Key features of the study:
This report provides in-depth analysis of the global humira biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market
Humira Biosimilar Market Detailed Segmentation:
By Product Type:
Biosimilar Humira (Adalimumab)
Interchangeable Biosimilar Humira
By Indication:
Rheumatoid Arthritis
Psoriasis
Crohn's Disease
Ulcerative Colitis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
Other Autoimmune Conditions
By Patient Age:
Adult Patients
Pediatric Patients
Geriatric Patients
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Company Profiles:
Amgen
Samsung Bioepis Co., Ltd.
Sandoz International GmbH (Novartis AG)
Mylan N.V.
Boehringer Ingelheim International GmbH
Pfizer Inc.
Fresenius Kabi AG
Coherus BioSciences, Inc.
Biogen Inc.
AbbVie Inc.
Celltrion Inc.
Rani Therapeutics Holdings, Inc.
Teva Pharmaceutical Industries Ltd
Merck & Co., Inc.
Viatris Inc.
Alvotech
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Product Type
Market Snippet, By Indication
Market Snippet, By Distribution Channel
Market Snippet, By Patient Age
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Patent expiration
Cost savings
Increasing prevalence of autoimmune diseases
Favorable regulatory environment
Market Restraints
Market Opportunity
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers Acquisitions, and Collaborations
4. Global Humira Biosimilar Market - Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Humira Biosimilar Market, By Product Type, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Biosimilar Humira (Adalimumab)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Interchangeable Biosimilar Humira
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
6. Global Humira Biosimilar Market, By Indication, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Rheumatoid Arthritis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Psoriasis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Crohn's disease
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Ulcerative Colitis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Ankylosing Spondylitis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Juvenile Idiopathic Arthritis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Other Autoimmune Conditions
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
7. Global Humira Biosimilar Market, By Patient Age, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Adult Patients
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Pediatric Patients
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Geriatric Patients
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
8. Global Humira Biosimilar Market, By Distribution Channel, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
9. Global Humira Biosimilar Market, By Region, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2025 and 2032 (%)
Y-o-Y Growth Analysis, For Region, 2021 -2032
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country/ Region, 2020-2032, (US$ Mn)
